Research Analysts’ Recent Ratings Updates for Surgery Partners (SGRY)

A number of research firms have changed their ratings and price targets for Surgery Partners (NASDAQ: SGRY):

• 8/11/2026 – Surgery Partners was given a new $18.00 price target by Raymond James Financial, Inc..
• 8/11/2026 – Surgery Partners had its “buy” rating reaffirmed by Benchmark Co..
• 8/11/2026 – Surgery Partners had its “buy” rating reaffirmed by TD Cowen. They now have a $19.00 price target on the stock, up from $17.00.
• 8/11/2026 – Surgery Partners had its price target lowered by Royal Bank Of Canada from $20.00 to $19.00. They now have an “outperform” rating on the stock.
• 8/11/2026 – Surgery Partners had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $18.00 price target on the stock.

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.